A Phase II study of HBI0101 (NXC-201) BCMA-CART in Multiple Myeloma and Light-chain Amyloidosis Patients. The goal of the study is to evaluate the efficacy and safety of HBI0101 CART.

开始日期2025-03-01

申办/合作机构

Hadassah University Hospital

NCT07085676

/ Recruiting临床1期IIT

A Phase 1 Dose Escalation and Safety Study of HBI0101 CART in B-cell Mediated Refractory Autoimmune Diseases

A Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the maximum HBI0101 CART dose that may be administered safely to patients with B-cell mediated autoimmune disease.

开始日期2024-09-01

申办/合作机构

Hadassah University Hospital

NCT06097832

/ Recruiting临床1/2期

Phase 1b/2 Study of NXC-201 for the Treatment of Patients With Relapsed or Refractory AL Amyloidosis

Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).

开始日期2024-06-05

申办/合作机构

Nexcella, Inc.

[+1]

100 项与 Revlucabtagene Autoleucel 相关的临床结果

登录后查看更多信息

100 项与 Revlucabtagene Autoleucel 相关的转化医学

登录后查看更多信息

100 项与 Revlucabtagene Autoleucel 相关的专利（医药）

登录后查看更多信息

项与 Revlucabtagene Autoleucel 相关的文献（医药）

2025-04-24·JOURNAL OF MEDICINAL CHEMISTRY

Identification of JNJ-61803534, a RORγt Inverse Agonist for the Treatment of Psoriasis

Article

作者: Cummings, Maxwell D. ; Albers, Michael ; Hoffmann, Thomas ; Goldberg, Steven D. ; Kleymann, Gerald ; Steeneck, Christoph ; Milligan, Cynthia ; Tanis, Virginia M. ; Venkatesan, Hariharan ; Sales, Zachary S. ; Fourie, Anne M. ; Schlüter, Thomas ; Schoetens, Freddy ; Spurlino, John ; Xue, Xiaohua ; Gege, Christian ; Scott, Brian ; Kinzel, Olaf ; Sepassi, Kia ; Edwards, James P. ; Coe, Kevin

The retinoic acid receptor-related orphan receptor gamma t (RORγt) is a nuclear transcription factor expressed in both innate and adaptive immune cells, driving Th17 cell differentiation and IL-17 production. The IL-23/IL-17 pathway is implicated in autoimmune and inflammatory diseases, and biologics that target IL-23/IL-17 signaling are efficacious in the treatment of psoriasis and psoriatic arthritis. RORγt, at the core of this pathway, represents an attractive opportunity for small-molecule intervention; however, combining high potency, nuclear receptor selectivity, and good physicochemical properties remains a challenge for RORγt inverse agonists. Recently, thiazole amides have been identified as potent RORγt inverse agonists; however, they often suffer from CYP450 autoinduction in the rat, precluding further development. Herein, we describe the discovery and development of potent and selective thiazole bisamide RORγt inverse agonists that avoid autoinduction in the rat. This effort culminated in the discovery of JNJ-61803534, which advanced into phase 1 clinical trials.

2024-08-13·Blood Advances

Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma

Article

作者: Grisariu, Sigal ; Avni, Batia ; Shehadeh, Alaa ; Kenett, Ron S ; Bessig, Nomi ; Elias, Shlomo ; Cohen, Yael ; Stepensky, Polina ; Lebel, Eyal ; Vainstein, Vladimir ; Gatt, Moshe E ; Cohen, Cyrille J ; Zimran, Eran ; Avivi, Irit ; Gatt, Moshe E. ; Dubnikov Sharon, Tatyana ; Cohen, Cyrille J. ; Asherie, Nathalie ; Alexander-Shani, Rivka ; Assayag, Miri ; Pick, Marjorie ; Zelmanovich, Veronica ; Kenett, Ron S. ; Roziner, Ilan ; Kfir-Erenfeld, Shlomit ; Ishtay, Aseel

Abstract:

HBI0101 is an academic chimeric antigen receptor T-cell (CART)–targeted to B-cell maturation antigen (BCMA) for the treatment of relapsed and refractory multiple myeloma (R/RMM) and light chain amyloidosis. Herein, we present the phase 1b/2 results of 50 heavily pretreated patients with R/RMM dosed with 800 × 106 CART cells. Inclusion criteria were relatively permissive (i.e., performance status and baseline organ function) and consequently, approximately half of the enrolled patients would have been ineligible for pivotal clinical trials. The median time elapsed from patient enrollment until CART delivery was 25 days (range, 14-65). HBI0101-related toxicities included grade 1 to 3 cytokine release syndrome, grade 3 to 4 hematologic toxicities, and grade 1 to 2 immune effector cell–associated neurotoxicity syndrome. Responses were achieved in 90% of the patients, 56% achieved stringent and complete response, and 70% reached a minimal residual disease negativity. Within a median follow-up of 12.3 months, the median progression-free survival (PFS) was 11.0 months (95% confidence interval [CI], 6.2-14.6), and the overall survival was not reached (95% CI, 13.3 to not reached). Multivariable analysis on patient/disease and CART-related characteristics revealed that high-risk cytogenetic, extramedullary disease, and increased number of effector-memory T cells in CART products were independently associated with inferior PFS. In conclusion, comprehensive analyses of the parameters affecting the response to CART therapy are essential for improving patients’ outcome. This trial was registered at www.ClinicalTrials.gov as #NCT04720313.

2022-12-01·Clinical cancer research : an official journal of the American Association for Cancer Research

Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis

Article

作者: Shaulov, Adir ; Avni, Batia ; Pick, Marjorie ; Assayag, Miri ; Gatt, Moshe E. ; Cohen, Cyrille J. ; Cohen, Yael C. ; Asherie, Nathalie ; Lebel, Eyal ; Avivi, Irit ; Stepensky, Polina ; Zimran, Eran ; Sharon, Tatyana Dubnikov ; Grisariu, Sigal ; Kfir-Erenfeld, Shlomit

Abstract:

Purpose::

AL amyloidosis (AL) treatments are generally based on those employed for multiple myeloma. Anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T (CART)-cell therapy, already approved for multiple myeloma, might be too toxic for patients with AL.

Experimental Design::

Here we describe the ex vivo applicability of a novel in-house, academic anti-BCMA CAR construct on AL primary cells, as well as the safety and efficacy in 4 patients with relapsed/refractory (RR) primary AL, treated in a phase I clinical trial (NCT04720313).

Results::

Three had MAYO stage IIIa cardiac involvement at enrollment. The treatment proved relatively safe, with a short and manageable grade 3 cytokine release syndrome evident in 2 patients and no neurotoxicity in any. Cardiac decompensations, observed in 2 patients, were also short and manageable. The overall hematologic response and complete response rates were observed in all patients with an organ response evident in all four. Within a median follow-up period of 5.2 (2.5–9.5) months, all 4 patients maintained their responses.

Conclusions::

BCMA-CART cells provide a first proof-of-concept that this therapy is safe enough and highly efficacious for the treatment of patients with advanced, RR AL.

147

项与 Revlucabtagene Autoleucel 相关的新闻（医药）

2025-11-03

·GlobeNewswire-Health Care

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

- Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that Phase 1/2 interim results from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming American Society of Hematology 2025 Annual Meeting (ASH 2025) being held in Orlando, Florida, December 6–9, 2025. ASH 2025 Presentation Details – NXC-201 Title“First 20-patient safety and efficacy data from NEXICART-2, the first U.S. trial of CAR-T in R/R light chain (AL) amyloidosis, NXC-201”Presentation Date/Time (Eastern Time) Presentation Date: December 7, 2025Presentation Time: 5:45 PM - 6:00 PM ETPresentation Abstract Number: abs25-14730Session Name: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: New therapies and treatment goals for AL amyloidosis Event details are available on the Immix website in the Presentation & Events section at https://immixbio.com/investors/#investor-presentation . About AL AmyloidosisAL amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead continuously produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 37,270 patients in 2025. The Amyloidosis market was $3.6 billion in 2017, and is expected to reach $6 billion in 2025, according to Grand View Research. About NXC-201NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy with a “digital filter” that filters out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the FDA, and Orphan Drug Designation (ODD) by the US FDA and in the EU by the EMA. About NEXICART-2NEXICART-2 (NCT06097832) is an ongoing multi-site U.S. Phase 1/2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational design. Interim results were presented at ASCO 2025 in an oral presentation. NEXICART-2 is expected to enroll 40 patients. About Immix Biopharma, Inc.Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed/refractory AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that filters out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com. Forward Looking StatementsThis press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, the potential benefits of our product candidate CAR-T NXC-201 and the timing and results related to clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1/2 clinical trials for CAR-T NXC-201 will not be favorably consistent with the data readouts to date, (ii) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (iii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iv) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (v) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (vi) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2025 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. ContactsMike MoyerLifeSci Advisorsmmoyer@lifesciadvisors.com Company Contactirteam@immixbio.com

ASH会议细胞疗法临床结果孤儿药临床研究

2025-10-01

·GlobeNewswire-Health Care

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

Los Angeles, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it will present and host institutional investor meetings at the 37th Annual Piper Sandler Healthcare Conference being held on December 2-4, 2025 at the Lotte New York Palace Hotel in New York, NY. The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Piper Sandler representative to request meetings. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section. About Immix Biopharma, Inc.Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that filters out non-specific activation. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NEXICART-2 primary endpoint was met at interim results presented at ASCO 2025. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com. Forward Looking StatementsThis press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, the potential benefits of our product candidate CAR-T NXC-201 and the timing and results related clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1/2 clinical trials for CAR-T NXC-201 will not be favorably consistent with the data readouts to date, (ii) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (iii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iv) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (v) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (vi) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2025 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. ContactsMike MoyerLifeSci Advisorsmmoyer@lifesciadvisors.com Company Contactirteam@immixbio.com

细胞疗法免疫疗法临床研究孤儿药临床结果

2025-09-11

·GlobeNewswire-Health Care

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

– Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far – Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Company”, “We” or “Us”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that Nancy T. Chang, former Tanox, Inc. CEO and proven biotechnology leader, has joined the Immix Biopharma Board of Directors concurrent with her investment as founding member of Goose Capital. At Tanox, Dr. Chang and her team invented and developed FDA-approved XOLAIR® (omalizumab) for severe asthma, TROGARZO® (ibalizumab-uiyk) for HIV, and EBGLYSS® (lebrikizumab-lbkz) for dermatitis, collectively generating drug sales exceeding 5 billion dollars so far. Tanox, Inc. was acquired by Genentech/Roche for $919 million. EBGLYSS® is commercialized by Eli Lilly and Co. About Immix Biopharma, Inc.Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that filters out non-specific activation. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NEXICART-2 primary endpoint was met at interim results presented at ASCO 2025. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com. Forward Looking StatementsThis press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, the potential benefits of our product candidate CAR-T NXC-201 and the timing and results related clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1/2 clinical trials for CAR-T NXC-201 will not be favorably consistent with the data readouts to date, (ii) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (iii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iv) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (v) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (vi) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2025 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. ContactsMike MoyerLifeSci Advisorsmmoyer@lifesciadvisors.com Company Contactirteam@immixbio.com

细胞疗法孤儿药上市批准免疫疗法临床研究

100 项与 Revlucabtagene Autoleucel 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
免疫球蛋白轻链淀粉样变性	临床2期	美国	Nexcella, Inc.	2024-06-05
多发性骨髓瘤	临床2期	美国	Immix Biopharma, Inc.	-
BCMA阳性多发性骨髓瘤	临床1期	以色列	Nexcella, Inc.	2021-01-01
难治性多发性骨髓瘤	临床1期	以色列	Nexcella, Inc.	2021-01-01
自身免疫性疾病	临床前	以色列	Nexcella, Inc.	2024-03-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT07085676 (ASN2025) 人工标引	临床1期	自身免疫性疾病	3	HBI0101	繭醖醖選築窪製窪鹽築(膚繭觸夢願顧窪餘鑰顧) = Treatment was well tolerated. One patient developed mild cytokine release syndrome; another developed hypogammaglobulinemia, managed with IVIG. No serious infections occurred. 遞廠鹹遞蓋鏇衊範構齋 (網獵膚廠齋遞製壓鹽鹽 )	积极	2025-11-08
NCT06097832 (NEXICART-2, ASCO2025)	临床1/2期	免疫球蛋白轻链淀粉样变性 BCMA	40	NXC-201	醖壓網獵鑰獵鹽廠齋蓋(廠積顧簾憲簾憲窪積淵) = CRS was observed in 5 pts (grade 1 (N=4), grade 2 (N=1)); onset day 1 (N=3) or 3 (N=2), lasting <24 hours following 1 dose of tocilizumab in all pts 壓糧選糧獵鹹鏇鏇蓋夢 (遞鑰遞蓋廠鹹範築壓鏇 ) 更多	积极	2025-05-30
NCT06097832 (NEXICART-2, NEWS) 人工标引	临床1/2期	免疫球蛋白轻链淀粉样变性	4	NXC-201 150 million CAR+T cells	築夢醖範範簾範觸遞憲(憲觸鏇製鹽廠膚願鬱築) = 積構壓繭繭糧夢鑰鏇鏇糧鬱鏇醖餘壓願獵願膚 (鬱獵壓糧壓繭積衊夢顧 ) 更多	积极	2024-12-19
NCT06097832 (NEXICART-2, NEWS) 人工标引	临床1/2期	免疫球蛋白轻链淀粉样变性	4	NXC-201 450 million CAR+T cells	窪鬱鹽範願窪構衊製蓋(觸糧餘艱築廠獵餘膚鏇) = 鏇願獵鹽簾鬱鬱膚窪積蓋廠艱窪廠製蓋鏇襯窪 (鹽夢衊蓋範繭鏇壓繭艱 ) 更多	积极	2024-12-19
NCT04720313 (HBI0101, Pubmed)	临床1/2期	复发性多发性骨髓瘤 high-risk cytogenetic \| extramedullary disease	50	HBI0101 (BCMA CART) therapy	鹽窪築餘蓋蓋鏇蓋廠網(窪鬱願顧觸壓鏇餘簾醖) = grade 1 to 3 cytokine release syndrome 壓積鬱觸繭構遞觸構淵 (糧壓鏇獵衊蓋獵鹽築齋 ) 更多	积极	2024-08-13
NCT04720313 (NEXICART-1, Biospace) 人工标引	临床1期	免疫球蛋白轻链淀粉样变性	13	NXC-201	鹹網構顧構廠觸鏇積夢(製鏇築鏇鑰鹹簾蓋餘鏇) = 築鬱觸壓醖積網積夢蓋選獵鬱膚鑰構網膚觸獵 (網醖鹽顧鏇願壓醖製築 ) 更多	积极	2024-05-10
NCT04720313 (NEXICART-1, Biospace) 人工标引	临床1期	免疫球蛋白轻链淀粉样变性	13	NXC-201 (pts not exposed to prior BCMA-targeted bispecific)	鹹網構顧構廠觸鏇積夢(製鏇築鏇鑰鹹簾蓋餘鏇) = 獵餘構網顧窪獵築鹹鑰選獵鬱膚鑰構網膚觸獵 (網醖鹽顧鏇願壓醖製築 ) 更多	积极	2024-05-10
ASH2023	临床1/2期	复发性多发性骨髓瘤	51	HBI0101	艱膚鹹鏇壓網壓鏇願衊(選構艱窪襯獵餘積廠獵) = 淵糧鑰積窪衊醖鹽選艱觸顧膚餘糧繭窪膚壓網 (淵醖糧鏇餘顧鑰積選夢 ) 更多	-	2023-12-11
NCT04720313 (ASH2023)	临床1/2期	免疫球蛋白轻链淀粉样变性	9	HBI0101 therapy	簾簾鹽壓鹹鹹夢製夢簾(膚齋遞鑰鏇選艱淵窪築) = 壓膚蓋鬱艱鬱壓獵繭製襯糧網艱蓋鏇網艱糧鏇 (觸齋簾壓夢鑰襯廠醖範 ) 更多	积极	2023-12-10
NCT04720313 (NEXICART-1, Corporate Publications) 人工标引	临床1/2期	免疫球蛋白轻链淀粉样变性	9	NXC-201 (heavily pre-treated patients with daratumumab relapsed/refractory AL Amyloidosis)	繭鑰齋鏇獵遞齋襯鏇遞(願膚襯窪衊願構鑰窪遞) = 遞淵艱獵積積範淵廠壓餘製鏇膚製願鹹淵鬱鏇 (憲積艱製餘蓋淵遞夢壓 ) 更多	积极	2023-10-03
NCT04720313 (NEXICART-1, Corporate Publications) 人工标引	临床1/2期	免疫球蛋白轻链淀粉样变性	9	NXC-201 (t(11;14) relapsed/refractory AL Amyloidosis)	繭鑰齋鏇獵遞齋襯鏇遞(願膚襯窪衊願構鑰窪遞) = 齋窪繭淵鏇壓顧選夢顧餘製鏇膚製願鹹淵鬱鏇 (憲積艱製餘蓋淵遞夢壓 ) 更多	积极	2023-10-03
NCT04720313 (IMS2023)	临床1期	复发性多发性骨髓瘤	50	HBI0101	艱選獵築憲獵餘夢鏇簾(醖窪壓選鹹顧膚淵觸選) = 觸遞構顧觸鑰鬱襯鑰積遞鹹構艱願夢窪鑰窪夢 (範願衊鹽憲蓋蓋壓膚窪 ) 更多	-	2023-09-26
NCT04720313 (GlobeNewswire) 人工标引	临床1期	多发性骨髓瘤	42	NXC-201	衊遞鏇衊齋齋願鬱廠齋(繭齋積鑰憲鹽廠窪獵製) = 構鹹鬱餘網鑰齋構遞壓蓋網獵網鑰製憲壓齋範 (鬱繭網網築觸衊構願艱 ) 更多	积极	2023-02-09
NCT04720313 (GlobeNewswire) 人工标引	临床1期	多发性骨髓瘤	42	NXC-201 (800 million CAR+T cells)	衊遞鏇衊齋齋願鬱廠齋(繭齋積鑰憲鹽廠窪獵製) = 鬱鬱壓顧獵襯餘膚積顧蓋網獵網鑰製憲壓齋範 (鬱繭網網築觸衊構願艱 ) 更多	积极	2023-02-09